- Home
- MRNA vs RDY Comparison
MRNA vs RDY Comparison
Compare MRNA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- RDY
- Stock Information
- Founded
- MRNA 2010
- RDY 1984
- Country
- MRNA United States
- RDY India
- Employees
- MRNA N/A
- RDY N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- MRNA Health Care
- RDY Health Care
- Exchange
- MRNA Nasdaq
- RDY Nasdaq
- Market Cap
- MRNA 10.9B
- RDY 11.8B
- IPO Year
- MRNA 2018
- RDY N/A
- Fundamental
- Price
- MRNA $24.47
- RDY $14.62
- Analyst Decision
- MRNA Hold
- RDY Strong Buy
- Analyst Count
- MRNA 19
- RDY 2
- Target Price
- MRNA $43.50
- RDY $16.95
- AVG Volume (30 Days)
- MRNA 9.9M
- RDY 855.1K
- Earning Date
- MRNA 11-06-2025
- RDY 11-04-2025
- Dividend Yield
- MRNA N/A
- RDY 0.49%
- EPS Growth
- MRNA N/A
- RDY 2.20
- EPS
- MRNA N/A
- RDY 0.79
- Revenue
- MRNA $3,078,000,000.00
- RDY $3,897,394,052.00
- Revenue This Year
- MRNA N/A
- RDY $7.33
- Revenue Next Year
- MRNA $10.17
- RDY $1.96
- P/E Ratio
- MRNA N/A
- RDY $18.43
- Revenue Growth
- MRNA N/A
- RDY 15.86
- 52 Week Low
- MRNA $23.15
- RDY $12.26
- 52 Week High
- MRNA $79.96
- RDY $16.19
- Technical
- Relative Strength Index (RSI)
- MRNA 38.50
- RDY 59.94
- Support Level
- MRNA $23.78
- RDY $14.15
- Resistance Level
- MRNA $25.48
- RDY $14.35
- Average True Range (ATR)
- MRNA 1.09
- RDY 0.16
- MACD
- MRNA 0.05
- RDY 0.04
- Stochastic Oscillator
- MRNA 25.00
- RDY 97.32
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.